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A B S T R A C T   
Background: Studies exploring the associations between perfluoroalkyl acids (PFAAs) and type 2 diabetes mel-
litus (T2DM) are rather limited and have reported conflicting results. All studies to date, including prospective 
ones, have relied on a single blood sample to study this association. Similarly, studies investigating how T2DM 
status may influence the longitudinal changes in PFAA concentrations have not been previously performed. As 
PFAA concentrations in humans have changed considerably over the last two decades, and as individuals di-
agnosed with T2DM usually undergo lifestyle changes that could influence these concentrations, a single blood 
sample may not necessarily reflect the life-time exposure to PFAA concentrations. Hence, repeated measure-
ments from the same individuals will extend our understanding of how PFAAs are associated with T2DM. The 
present study, therefore, aimed to explore associations between pre- and post-diagnostic PFAA blood profiles and 
T2DM and assess factors associated with longitudinal changes in PFAAs in T2DM cases and controls. 
Methods: Questionnaire data and blood samples from women participating in the Norwegian Women and Cancer 
study were used to conduct a nested case-control study among 46 T2DM cases matched to 85 non-diabetic 
controls. PFAAs were measured in blood samples collected prior to (2001/02) and after (2005/6) T2DM diag-
nosis. We investigated the association between PFAAs and incident and prevalent T2DM using conditional lo-
gistic regression. We assessed the longitudinal changes in PFAA concentrations within and between matched 
cases and controls using t-tests and linear regression models. 
Results: We observed no significant associations between pre-diagnostic PFAA concentrations and T2DM in-
cidence. Similar results were observed for the post-diagnostic PFAA concentrations and T2DM prevalence. 
Decrease over time in PFAA concentrations were observed for PFOA and ∑PFOS concentrations, whereas in-
crease over time were observed for PFNA, PFDA and PFUnDA concentrations. Longitudinal trends in PFAA 
concentrations among T2DM cases were similar to the changes observed in controls. 
Conclusions: The study did not find evidence of association between PFAAs and incident or prevalent T2DM. The 
longitudinal changes in PFAAs concentrations were not influenced by T2DM status.   
1. Introduction 
The prevalence of type 2 diabetes mellitus (T2DM), a metabolic 
condition characterized by elevated blood glucose levels, has increased 
alarmingly worldwide and accounts for 90% of all diabetes (Saeedi 
et al., 2019). The estimated global prevalence of diabetes was 9.3% 
(463 million people) in 2019, and projections suggest that it will rise to 
10.2% by 2030 and 10.9% by 2045 (Saeedi et al., 2019). Well-estab-
lished risk factors of T2DM include older age, obesity, sedentary life-
style, and genetic predisposition. Diet is considered a risk factor for 
T2DM, however, previous studies have shown that dietary factors as-
sociated with increased risk for T2DM are linked with other unhealthy 
lifestyle factors which showed highly significant associations with 
T2DM, such as physical inactivity and increased BMI (Aune et al., 2009; 
Bellou et al., 2018; Imamura et al., 2015). However, recent research has 
implied that other non-traditional factors like stress, epigenetic 
changes, and various environmental organic pollutants may also con-
tribute to the increased prevalence of T2DM (Magliano et al., 2014; 
McAllister et al., 2009). 
Legacy persistent organic pollutants, such as polychlorinated 
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biphenyls (PCBs) and organochlorine pesticides (OCPs), are endocrine 
disrupting chemicals that may play a role in the development of me-
tabolic conditions like T2DM (Alonso-Magdalena et al., 2011; Nadal 
et al., 2017; Taylor et al., 2013). However, evidence for emerging 
pollutants like perfluoroalkyl substances (PFASs) is rather limited. 
PFASs are a class of organofluorine compounds that have been 
widely used in industrial and consumer products since the 1950s. Many 
PFASs are persistent and accumulate in the environment and in biota; 
today, the main route of human exposure to PFASs is through diet (Lin 
Pi et al., 2020; Vestergren et al., 2008; Vestergren and Cousins, 2009). 
Other sources of exposure include PFAS-treated clothing, food packa-
ging materials, and cooking utensils, but also dust inhalation and skin 
absorption (Haug et al., 2011; Lau, 2015; Nadal et al., 2017). The most 
frequently detected of such compounds in human blood are per-
fluoroalkyl acids (PFAAs), a subclass of the PFAS family, in which 
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) 
are the most frequently studied. The elimination half-lives of PFAAs 
were estimated to be 3.5–8.5 years (Olsen et al., 2007a). 
PFAAs are classified as endocrine disrupting chemicals (Lind and 
Lind, 2018). They have a chemical structure that resembles that of fatty 
acids, a feature that enables them to bind to and activate peroxisome 
proliferator-activated receptors. These receptors play an important role 
in lipid and glucose metabolism and in the regulation of energy 
homeostasis (Jiang et al., 2015; Lind et al., 2014; Wolf et al., 2008). 
Therefore, pharmaceutical drugs target these receptors for the treat-
ment of dyslipidemia and T2DM. Since PFAAs bind to the same re-
ceptors, the effects that PFAAs may have on glucose metabolism are 
worth exploring (Lind et al., 2014). Other proposed mechanisms in-
clude effects of PFAAs on thyroid and steroid hormones which play a 
major role in adipocyte differentiation and energy storage which in turn 
may increase the risk of T2DM (Hatch et al., 2010). Animal studies have 
established no direct link between PFAA exposure and the pathogenesis 
of T2DM (Khalil et al., 2015). However, findings from both cross-sec-
tional and prospective studies of PFAA concentrations in the blood of 
humans have reported inconsistent results: some studies have reported 
null (Cardenas et al., 2017; Karnes et al., 2014; Lind et al., 2014) or 
inverse associations (Donat-Vargas et al., 2019; MacNeil et al., 2009), 
and a few studies have reported positive associations (Christensen et al., 
2016; He et al., 2018; Sun et al., 2018). Thus, the role of circulating 
PFAA concentrations in the development of T2DM is uncertain and 
needs to be further investigated with prospective studies. In addition, 
all studies to date have reported results from a single blood sample 
collected either prior or after T2DM diagnosis. As the general Norwe-
gian population experienced a considerable increase in PFAA con-
centrations until the year 2001 (Nøst et al., 2014), followed by a sig-
nificant decline, a single blood sample may not reflect lifetime exposure 
to PFAAs. Further, after T2DM diagnosis, many patients adopt lifestyle 
changes and are prescribed glucose-lowering drugs; both of these fac-
tors may affect the concentration of fat-soluble PCBs and OCPs (Tornevi 
et al., 2019). Little is known about whether and how these factors in-
fluence PFAA concentrations in T2DM patients. Therefore, the present 
study aimed to explore associations between pre- and post-diagnostic 
PFAA blood profiles and T2DM among T2DM cases and controls and 
explore the factors influencing the longitudinal trends in PFAAs con-
centrations using a longitudinal, nested case-control design. 
2. Materials and methods 
2.1. The Norwegian Women and Cancer study 
The Norwegian Woman and Cancer (NOWAC) study, established in 
1991, is an ongoing, population-based, prospective cohort study. The 
cohort is nationally representative and consists of over 170,000 women 
(30–70 years of age) who have answered between one and four ex-
tensive questionnaires on diet, lifestyle factors, medications, and self- 
reported diseases (Lund et al., 2008). Approximately, 50,000 
participants have also given blood samples, which are stored at −80 °C, 
and completed a questionnaire about their use of medications at the 
time of blood collection. A total of 7849 women donated blood samples 
at two separate time points: time point 1 (T1) in 2001/02 and time 
point 2 (T2) in 2005/06. A detailed description of blood collection 
procedures has been reported elsewhere (Waaseth et al., 2008). 
2.2. Study design and participants 
This is a longitudinal, 1:2 individually-matched, nested case-control 
study. T2DM cases were defined as those reporting diabetes in the 
NOWAC questionnaire and/or reporting the use of diabetes medication 
at T2. This questionnaire information has been previously validated 
against medical journals/doctors confirmation in the NOWAC study 
(Rylander et al., 2014). Of the 7849 women who provided blood 
samples at T1 and T2, 53 were free of T2DM at T1 and reported T2DM 
at T2. Blood samples collected at T1 were then defined as pre-diagnostic 
samples (among cases) and those taken at T2 as post-diagnostic sam-
ples. Women with cancer, and those with an insufficient amount of 
plasma available were excluded, as were women with diabetes who 
were taking insulin (to ensure that no type 1 diabetes cases were in-
cluded), leaving 46 T2DM cases in the analytical sample. Each T2DM 
case was then matched with two diabetes-free controls; control 1 was 
matched on birth year ( ± 1 year) at T1 and year of blood collection at 
T2; control 2 was matched on birth year ( ± 1 year) at T1, body mass 
index (BMI) ( ± 3 kg/m2) at T2, and year of blood collection at T1 and 
T2. Our study is part of a larger study that intended to explore the 
relationship between lipophilic PCBs, OCPs, and hydrophilic PFAAs and 
T2DM. Since evidence shows that BMI is directly linked with both PCBs, 
OCP concentrations and T2DM (a confounder), we matched control 
group 2 on BMI at T2. Due to lack of sufficient plasma volume, two 
controls from control group 1 were excluded. In control group 2, only 
41 available controls could be matched on both birth year and BMI. 
Thus, case-control group 1 consisted of 44 matched pairs and case- 
control group 2 consisted of 41 matched pairs. 
2.3. Questionnaire data 
Information on covariates was retrieved from NOWAC ques-
tionnaires. Each participant answered five questionnaires (Qs), in 1991 
(Q1), 1998 (Q2), 2001/02 (Q3), 2004/05 (Q4), and 2005/06 (Q6). 
These questionnaires included detailed information on demographics, 
lifestyle factors, dietary factors, anthropometrics, health related ques-
tions, use of medications, and information on parity and total months of 
breastfeeding. Age, weight, and height were reported in all ques-
tionnaires except Q3 (filled out at T1). Information on breastfeeding 
and parity was only reported in Q1 and Q2. 
2.4. Chemical analysis 
A total of 18 PFAAs were analyzed at the Department of Laboratory 
Medicine, University Hospital of North Norway (Table A.1). The pro-
cedures for sample preparation, instrumental analysis, quantification, 
and quality control for PFASs have been previously described in detail 
(Huber and Brox, 2015). In short, an automated liquid handler (Tecan 
Freedom Evo 200, Männedorf, Switzerland) was used for the prepara-
tion of extracts, where 50 µL of plasma was applied. Instrumental 
analysis was conducted on a Waters Acquity ultra-high-pressure liquid 
chromatography system coupled to a Waters Xevo-TQ-S tandem mass- 
spectrometer (both Waters, Milford, MA, USA). Electrospray ionization 
in negative mode was applied for ionization of the analytes and multi- 
reaction monitoring mode for recording of the transitions. For quality 
assurance, four blank samples, four standard reference material (SRM) 
1958 and SRM 1957 (NIST, Gaithersburg, MD, USA), and three bovine 
serum samples (Sigma Aldrich, Steinheim, Germany) were prepared 
and analyzed within each batch of 96 samples in order to control 
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background and carry-over. All the quality controls were within ac-
ceptable limits (within three times the standard deviation from the 
reference concentrations, together with a relative standard deviation of 
≤15%), and all PFAA analyses were within the acceptable ranges (z- 
score of ≤1) of the international quality control program: the Arctic 
Monitoring and Assessment Ring Test for Persistent Organic Pollutants 
in Human Serum (organized by the Laboratoire de toxicologie, Institut 
National de Santé Publique du Quebec, Canada). 
2.5. Statistical analysis 
All statistical analyses were performed using STATA software, ver-
sion 16 (StataCorp, 4905 Lakeway Drive, College Station, TX, USA). 
Only those PFAAs that had a detection frequency ≥90% were included 
in the statistical analyses. These included seven PFAA compounds – four 
perfluoroalkyl carboxylic acids: PFOA, perfluoronanoic acid (PFNA), 
perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid 
(PFUnDA); and three perfluoroalkyl sulfonic acids: perfluorohexane 
sulfonate (PFHxS), perfluoroheptane sulfonate (PFHpS), and PFOS. 
PFAA concentrations below their individual method detection limits 
(MDL) were replaced by MDL divided by 2 (Table A.1). The linear and 
branched forms of PFHxS, PFHpS, and PFOS were summed and pre-
sented as ∑PFHxS, ∑PFHpS, and ∑PFOS, respectively. The individual 
PFAA compounds were ranked in the order of lowest to highest. The 
sum of the ranks of PFNA, PFOA, PFDA, PFUnDA, ∑PFHxS, ∑PFHpS, 
and ∑PFOS concentrations is presented as ∑PFAAs. Spearman correla-
tions were performed to examine the linear relationship between dif-
ferent PFAAs at the two different time-points. 
Descriptive statistics at T1 are presented as mean and standard 
deviation (SD) for demographic data and median (5th, 95th percentiles) 
for PFAA concentrations (ng/mL). We compared demographics and 
PFAA concentrations between cases and matched controls at T1 and T2 
(mean in cases-mean in controls) using one-sample t-tests. We also 
tested whether the longitudinal changes (δ) within individuals from T1 
to T2 were significantly different from zero (T2 measurement – T1 
measurement) using paired t-tests. Comparison of trends between cases 
and controls (longitudinal changes in cases – longitudinal changes in 
controls) were analyzed using one-sample t-tests. Thus, we tested the 
null hypothesis that the longitudinal change in cases equaled the 
longitudinal change in controls. In order to control for confounding 
factors and identify factors associated with the longitudinal changes in 
PFAAs, we performed linear regression models using the longitudinal 
changes in PFAA concentration from T1 to T2 as dependent variables. 
Age at T1 centered around the mean age of 52, BMI at T1 centered 
around BMI = 25 kg/m2, dietary changes (fish, meat, dairy, fruits and 
vegetables) and weight change from T1 to T2 were included as in-
dependent variables. We did not consider changes in parity and 
breastfeeding in the linear regression models as the participants were 
over 50 years of age at T1. BMI at T1 and weight change from T1 to T2 
served as proxies for the matching on BMI at T2 for case-control group 
2. 
The association between pre-diagnostic PFAA concentrations and 
odds of T2DM at T1 were examined using multivariable conditional 
logistic regression. The covariates considered were age, breastfeeding 
and dietary factors (meat, fish, diary, fruit and vegetables). The selec-
tion of covariates was based on previous literature and drawing a di-
rected acyclic graph (DAG) showing the assumed relations between 
PFAAs, T2DM, and the different covariates (Fig. 1). Weight and height 
at T1 were extracted from Q2. Since breastfeeding and parity were 
found to be highly correlated, only breastfeeding was considered for the 
logistic regression models. The covariates identified from the DAG was 
also included in the conditional logistic regression models exploring the 
associations between the post-diagnostic PFAA concentrations and 
prevalent T2DM. The results are presented as odds ratios (ORs) with 
95% confidence intervals (CIs). ORs are estimated per 1 interquartile 
range (IQR) increase in PFAA concentrations and 50 ranks increase in 
∑PFAAs. All p-values were two-sided, and a 5% level of significance was 
used. 
3. Results 
3.1. Study sample characteristics 
At T1 (pre-diagnosis), the mean age and BMI for the whole study 
sample were 52.0 years and 26.9 kg/m2, respectively. Cases had sig-
nificantly higher weight than both control groups and higher meat in-
take compared to control group 2. However, there were no significant 
differences in parity, breastfeeding or the other dietary factors. At T2, 
only BMI was significantly higher in cases compared to control group 1. 
No differences in demographic variables or dietary factors were ob-
served between cases and control group 2 (Table 1). 
At both time points, ∑PFOS and PFOA were the two most prevalent 
PFAAs measured in both cases and controls. No significant differences 
were observed in mean PFOA, PFNA, PFDA, PFUnDA, ∑PFHxS, ∑PFHpS 
and ∑PFOS concentrations between cases and control groups at T1. At 
T2, cases had significantly lower PFOA concentrations compared to 
control group 2, whereas there were no differences across case-control 
pairs for any of the other PFAAs at T2 (Table 1). Strong positive cor-
relations were observed between the different PFAAs at both the time- 
points with the correlation coefficient (rs) ranging between 0.52–0.92 
at T1, and 0.54–0.90 at T2 (Table A.2). 
3.2. Longitudinal changes within cases and controls 
Within cases, there were no significant changes in weight, BMI, 
parity, or breastfeeding from T1 to T2. Cases showed no mean differ-
ence in dietary factors from T1 to T2 (Table A.3). PFOA and ∑PFOS 
concentrations significantly decreased, whereas PFNA, PFDA, PFUnDA, 
and ∑PFHxS concentrations increased significantly from T1 to T2. 
∑PFHpS showed no significant changes (Fig. 2, Table A.3). Both control 
groups increased significantly in weight, BMI, fruits and vegetables 
intake from T1 to T2, but there were no significant changes in parity, 
breastfeeding or fish intake. Reduced dairy intake in control group 1 
and increased meat intake in control group 2 were observed at T2 
(Table A.3). ∑PFOS decreased significantly in both control groups, and 
there were no significant changes in PFOA, ∑PFHxS, or ∑PFHpS con-
centrations. PFNA, PFDA, and PFUnDA concentrations increased sig-
nificantly from T1 to T2 in both control groups (Fig. 2, Table A.3) 
3.3. Longitudinal changes between cases and controls 
Mean change in weight and BMI between T1 and T2 were lower for 
cases compared to both control groups; however, this change was only 
statistically significant for the comparison of BMI between cases and 
control group 2. The crude longitudinal changes in PFAA concentra-
tions from T1 to T2 did not differ significantly between cases and 
control groups 1 or 2, except for ∑PFHpS, for which a significantly 
larger decline in concentration over time was observed among cases 
compared to both control groups (Fig. 2, Table A.4). However, after 
controlling for age and BMI at T1, changes in diet and body weight, 
T2DM status did not seem to influence the longitudinal trends in any of 
the PFAA compounds, but changes in PFAAs over time were rather 
driven by age and dietary factors (Table A.5). 
3.4. Pre-diagnostic and post-diagnostic associations 
After adjusting for relevant confounders, none of the PFAAs were 
significantly associated with increased or decreased odds of T2DM 
when measured at T1 (pre-diagnosis) or at T2 (post-diagnosis) (Tables 2 
and 3). Inverse associations for pre-diagnostic concentrations of PFOA 
and ∑PFHpS were observed for both case control groups. PFNA, PFDA, 
PFUnDA, ∑PFHpS, ∑PFOS, and ∑PFAAs concentrations showed inverse 
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associations for case-control group 1 and positive associations for case 
control group 2. However, none of the pre-diagnostic associations were 
statistically significant in the multivariable adjusted models for either 
of the case control groups. (Tables 2 and 3). Inverse and non-significant 
associations were observed between prevalent T2DM and post-diag-
nostic PFOA, PFNA, ∑PFHxS, ∑PFHpS, ∑PFOS, and ∑PFAA concentra-
tions, and positive, non-significant associations for PFDA and PFUnDA 
in the multivariable adjusted models for control group 2 (Tables 2 and 
3). 
4. Discussion 
In this study, none of the investigated PFAAs were significantly 
associated with increased odds of T2DM when measured prior to or 
after disease development. There were significant changes in PFAA 
concentrations from pre- to post-diagnosis within cases and controls; 
∑PFOS concentrations decreased and PFNA, PFDA, and PFUnDA con-
centrations increased within cases and both control-groups, whereas 
PFOA concentrations decreased and ∑PFHxS increased significantly 
within cases. However, the longitudinal changes were not significantly 
different in cases versus controls and were mainly explained by dif-
ferences in age and dietary intake after controlling for confounding 
factors. Thus, T2DM status did not influence the longitudinal changes in 
PFAAs. 
Overall, our study results of no associations between pre-diagnostic 
PFAA concentrations and incident T2DM are in line with the findings 
from other prospective studies. For instance, the most recent, pro-
spective, nested case-control study by Donat-Vargas et al. (2019) found 
inverse, mostly non-significant associations between pre-diagnostic 
PFAA concentrations (PFOA, PFDA, PFUnDA, PFHxS, and PFOS) and 
odds of T2DM in 124 case-controls pairs from the Swedish, prospective, 
population-based Västerbotten Intervention Programme cohort (Donat- 
Vargas et al., 2019). Another large prospective study conducted among 
residents of a community exposed to high levels of PFOA through 
drinking water (C8 Health project) presented a null association between 
PFOA and incident T2DM (n = 27,921; 814 cases). However, in that 
study, serum PFAA concentrations were only estimated and not mea-
sured (Karnes et al., 2014). A study conducted among overweight and 
obese individuals at high risk for T2DM (n = 957,204; T2DM cases) 
found no association between pre-diagnostic PFAA concentrations 
(PFNA, PFOA, ∑PFHxS, and ∑PFOS) and incident T2DM (Cardenas 
et al., 2017). In contrast to our results, positive, significant associations 
between pre-diagnostic PFOA concentrations (3rd vs. 1st tertile OR: 
1.54, 95% CI: 1.04, 2.28), PFOS concentrations (3rd vs. 1st tertile OR: 
1.62, 95% CI: 1.09, 2.41), and incident T2DM were reported by a re-
cent, prospective, nested case-control study (n = 1586, 793 T2DM 
cases) conducted among women from the United States Nurses Health 
Study II. No association was observed between T2DM and PFNA, PFDA, 
or ∑PFHxS in that study. However, they reported PFAA concentrations 
(median PFOA and ∑PFOS concentrations of 7.36 ng/mL and 56.3 ng/ 
mL, respectively) that were much higher than those we report in our 
study. Only the tertiles with the lowest concentrations (2.89 ng/mL for 
PFOA and 19.7 ng/ml for PFOS) were comparable to the concentrations 
in our sample (Sun et al., 2018). The different prospective studies vary 
in sample size, type of study participants (difference in gender, high- 
risk individuals, and general population or highly exposed individuals), 
median PFAA concentrations, year(s) of blood sampling, number of 
follow-up years, and statistical analyses. These differences make it 
difficult to extrapolate our findings to other prospective studies. For 
instance, evidence for increased risk of T2DM in general populations 
with high PFAA concentrations in the blood is still unclear. Thus, the 
dose–response relationship between different PFAA exposure con-
centrations and T2DM incidence in the general population needs fur-
ther attention. 
Similar to T1, at T2 (post-diagnosis), PFAA concentrations showed 
no associations with T2DM prevalence. In agreement with our results, 
previous studies that have examined this association also reported no 
associations between PFAAs and T2DM prevalence (He et al., 2018; 
Lind et al., 2014; MacNeil et al., 2009; Rylander et al., 2015). For in-
stance, He et al. (2018) conducted a large, cross-sectional study of 7904 
adults in the National Health and Nutrition Examination Survey in the 
United States. PFOA, PFNA, and PFHxS concentrations were slightly 
higher and PFOS was slightly lower in those samples compared to our 
study. They reported no association between serum PFOA and prevalent 
T2DM among women (n = 3948, OR: 1.47, 95% CI: 0.88, 2.46; P for 
trend = 0.737). However, a significant positive association was re-
ported among men in the same study (n = 3956, OR: 2.66, 95% CI: 
1.63, 4.35; P for trend = 0.001). The other PFAAs studied (PFNA, 
PFHxS, and PFOS) were not related to diabetes, regardless of gender 
(He et al., 2018). Other studies have also reported significant positive 
associations between certain PFAAs and prevalent T2DM in men 
(Christensen et al., 2016). Our study results are in agreement with 
previous studies that found no association between PFAAs and T2DM 
prevalence in women. The fact that other studies have observed sig-
nificant associations in men indicates that there could be gender-de-
pendent changes in PFAA concentrations after T2DM diagnosis. 
Fig. 1. Directed acyclic graph of the causal network 
between pre-diagnostic PFAAs and risk of type 2 
diabetes mellitus. (The different colors in the DAG 
represent the following: green-exposure; yellow-out-
come; pink-confounders; blue-mediators; grey- 
matching factors for control groups; arrows-direction 
of the pathways). (For interpretation of the refer-
ences to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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Table 1 
Demographic characteristics, dietary factors and PFAA concentrations of cases and controls and mean difference (Δ) between case-control pairs.            
T1 (pre-diagnosis) T2 (post-diagnosis)   
Mean (SD) Median 
(5, 95 percentiles) 
ΔMeancase-control 
(95% CI)e 
Mean (SD) Median 
(5, 95 percentiles) 
ΔMeancase-control 
(95% CI)e  
Case-control group 1 
Demographics 




55.0 (45.0, 58.0) 





58.5 (49.0, 61.0) 
58.0 (48.0, 62.0) 
0.20 
(−0.02, 0.43) 




75.0 (60.0, 120) 





77.0 (59.0, 110) 
74.0 (55.0, 112) 
5.34 
(−0.82, 11.5) 




27.6 (21.0, 39.6) 





28.3 (21.1, 40.6) 







2.00 (0.00, 4.00) 





2.00 (0.00, 4.00) 
2.00 (0.00, 4.00) 
0.18 
(−0.33, 0.70) 




10.0 (1.00, 36.0) 





10.0 (1.00, 36.0) 
7.00 (0.00, 24.0) 
3.69 
(−4.83, 5.22) 




84 (17.3, 193) 





89 (33.4, 178) 
75 (20.6, 228) 
−2.78 
(−26.4, 20.9) 




126 (52.1, 177) 





117 (71.9, 171) 
103 (40.1, 199) 
17.3 
(−1.22, 35.9) 




240 (41.1, 674) 





228 (23.6, 578) 
154 (30.9, 609) 
3.05 
(−69.2, 75.3) 




298 (67.5, 895) 





417 (130, 743) 
401 (150, 695) 
30.7 
(−62.1, 123)  





2.32 (1.00, 4.13) 





2.10 (0.75, 4.54) 







0.38 (0.18, 1.06) 





0.55 (0.26, 1.18) 







0.18 (0.07, 0.55) 





0.25 (0.12, 0.70) 







0.22 (0.11, 0.63) 





0.30 (0.12, 1.07) 







0.80 (0.36, 2.51) 





0.93 (0.33, 3.05) 
1.05 (0.43, 3.85) 
−0.18 
(−0.61, 0.26) 




0.33 (0.15, 0.61) 





0.30 (0.12, 0.58) 







20.1 (10.3, 37.9) 





16.0 (6.54, 32.0) 
16.0 (6.09, 65.4) 
−3.20 
(−9.69, 3.29)  
Case-control group 2 
Demographics 




55.0 (45.0, 58.0) 





58.0 (49.0, 61.0) 
57.0 (49.0, 61.0) 
−0.05 
(−0.47, 0.37) 




75.0 (60.0, 105) 





75.0 (58.0, 106) 
74.0 (60.0, 92.0) 
2.63 
(−0.98, 6.25) 




27.6 (21.0, 36.6) 





28.2 (20.7, 36.5) 







2.00 (0.00, 4.00) 





2.00 (0.00, 4.00) 
2.00 (1.00, 3.00) 
−0.20 
(−0.63, 0.24) 




8.00 (0.00, 36.0) 





8.00 (0.00, 36.0) 
9.00 (0.00, 30.5) 
0.19 
(−4.83, 5.22) 




84 (17.3, 173) 





89 (33.4, 178) 
73 (27.7, 224) 
−0.17 
(−23.4, 23.1) 




124 (60.4, 177) 





119 (71.9, 171) 
115 (46.1, 190) 
4.83 
(−12.1, 21.8) 




228 (41.1, 674) 





209 (23.6, 578) 
170 (33.9, 598) 
19.8 
(−71.3, 111) 




307 (67.5, 895) 





422 (130, 826) 
384 (251, 695) 
6.79 
(−58.0, 71.6)  





2.32 (0.99, 4.13) 





2.12 (0.75, 4.54) 







0.38 (0.18, 1.06) 





0.54 (0.26, 1.18) 







0.18 (0.07, 0.55) 





0.25 (0.12, 0.70) 







0.24 (0.11, 0.63) 





0.34 (0.13, 1.07) 







0.91 (0.36, 2.51) 





0.95 (0.33, 3.05) 







0.33 (0.15, 0.61) 





0.29 (0.12, 0.58) 
0.34 (0.13, 0.61) 
−0.02 
(−0.09, 0.05) 
(continued on next page) 
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Taken together, the results at T1 and T2, combined with observa-
tions from previous studies, suggest no clear role of PFAAs in T2DM 
pathogenesis or its progression in general populations with low back-
ground exposure. However, there are no previous studies from other 
populations with a similar study design to which we can compare our 
findings. 
Our study also examined the mean longitudinal changes in demo-
graphics and PFAA concentrations between the two blood measure-
ments (~4 years) within the same individuals and across the cases and 
control groups. From T1 to T2, cases maintained a stable weight, 
whereas both control groups increased in mean body weight. This could 
be attributed to lifestyle changes adopted by cases after being diag-
nosed with T2DM. When comparing PFAA concentrations within the 
cases, PFOA and ∑PFOS concentrations significantly decreased from T1 
to T2, whereas PFNA, PFDA, PFUnDA, and ∑PFHxS concentrations in-
creased significantly. Similar to the trends in cases, ∑PFOS decreased 
significantly, and PFNA, PFDA, and PFUnDA concentrations increased 
significantly from T1 to T2 in both control groups. However, there were 
no significant changes in PFOA, ∑PFHxS, or ∑PFHpS concentrations. 
These findings are in line with previous studies of time trends con-
ducted during the same time period that also included repeated mea-
surements of PFAAs within the same individuals (Nøst et al., 2014; 
Olsen et al., 2007b, 2012; Toms et al., 2014). These studies reported 
declining PFOA and PFOS concentrations and increasing PFNA, PFDA, 
and PFUnDA concentrations (Fitz-Simon et al., 2013; Nøst et al., 2014; 
Olsen et al., 2007b, 2012; Toms et al., 2014). Thus, our study followed 
the temporal trends that could be expected for most PFAAs based on 
studies in other populations. The mean PFAA concentrations at both 
time points and the decline in PFOA and PFOS concentrations from T1 
to T2 in our study were considerably lower than those in the studies 
mentioned above. One of the contributing factors could be the demo-
graphics of our study sample, which mainly included older women, 
among whom the decline in PFAA concentrations may be slower when 
compared to the younger women surveyed in previous studies. 
When comparing longitudinal changes in PFAAs across cases and 
controls, no significant differences were observed for any of the PFAA 
compounds between the groups after controlling for confounding fac-
tors. Thus, cases and controls decreased or increased in a similar 
manner, which suggests that T2DM diagnosis, use of T2DM medication, 
and weight changes or BMI following T2DM diagnosis in cases have 
limited influence on PFAA concentrations. The longitudinal changes in 
PFAAs were rather influenced by age and changes in diet. No other 
prospective studies have been conducted among T2DM cases and con-
trols with pre- and post-diagnostic PFAA measurements with which to 
compare the temporal changes observed in our study, suggesting the 
need for further longitudinal studies to explore intra-individual and 
inter-individual temporal changes in PFAAs between T2DM cases and 
controls, especially among individuals exposed to higher concentrations 
which would extend our understanding of how metabolic changes are 
related to PFAA concentrations. 
Table 1 (continued)           
T1 (pre-diagnosis) T2 (post-diagnosis)   
Mean (SD) Median 
(5, 95 percentiles) 
ΔMeancase-control 
(95% CI)e 
Mean (SD) Median 
(5, 95 percentiles) 
ΔMeancase-control 





19.1 (10.3, 37.9) 





15.5 (6.54, 32.0) 
18.6 (7.72, 34.1) 
−1.94 
(−6.51, 2.63) 
Abbreviations: PFAA, perfluoroalkyl acid; T1, time point 1 (2001/2); T2, time point 2 (2005/6); SD, standard deviation; CI: confidence interval; BMI, body mass 
index; PFOA, perfluorooctanoic acid; PFNA, perfluoronanoic acid; PFDA, perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; ∑PFOS, sum perfluorooctane 
sulfonate; ∑PFHxS, sum perfluorohexane sulfonate; ∑PFHpS, sum perfluoroheptane sulfonate. 
a Case group 1, n = 44. 
b Control group 1 matched on age at T1, n = 44. 
c Case group 2, n = 41. 
d Control group 2 matched on age at T1 and BMI at T2, n = 41. 
e Mean difference between matched case-control pairs and 95% CI around the mean.  
Fig. 2. Crude longitudinal changes (δ) in mean PFAA concentrations from T1 (2001/02, pre-diagnosis) to T2 (2005/06, post-diagnosis) in cases and control groups. 
†denotes significant change (paired t-test, p  <  0.05) between T1 and T2 within the group; ■ denotes significant (one sample t-test, p  <  0.05) difference in 
longitudinal change between cases and control group 1; ▾ denotes significant (one sample t-test, p  <  0.05) difference in longitudinal change between cases and 
control group 2. Abbreviations: PFAA, perfluoroalkyl acid; T1, time point 1; T2, time point 2 PFOA, perfluorooctanoic acid; PFNA, perfluoronanoic acid; PFDA, 
perfluorodecanoic acid; PFUnDA, perfluoroundecanoic acid; PFOS, perfluorooctane sulfonate; PFHxS, perfluorohexane sulfonate; PFHpS perfluoroheptane sulfonate. 
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This study is the first longitudinal study to measure plasma PFAA 
concentrations at two different time points, once prior to and once 
following T2DM diagnosis within the same individuals. This enabled us 
to examine the association between PFAAs and T2DM both pro-
spectively and cross-sectionally within the same individuals. Further, 
we were also able to observe longitudinal changes in the different PFAA 
compounds intra-individually and between T2DM cases and controls, 
which is novel. Rigorous laboratory quality control procedures re-
present an additional strength of the present study. Potential con-
founders were either negated by matching for age, BMI, and year of 
blood collection, or adjusted for in the analyses. We used two different 
control groups: one matched on age and the other on age and BMI. 
Studies have shown that that elevated PFAAs concentrations are asso-
ciated with weight gain/re-gain in obese individuals/individuals at 
high risk for T2DM undergoing a health intervention program 
(Cardenas et al., 2018; Liu et al., 2018). This may suggest that the re-
sults in our study show the indirect effect of PFAAs on T2DM masked by 
the matching on BMI for case-control group 2. However, previous stu-
dies from general populations (Barry et al., 2014; Blake et al., 2018; Lin 
et al., 2009; Nelson et al., 2010) have reported that PFAAs concentra-
tions are not associated to BMI and our overall results also show that 
the ORs were similar for both case-control groups in the pre- and post- 
diagnostic associations. Therefore, we find it unlikely that this is a large 
bias in our study. Although, we do agree that matching by BMI is un-
necessary in future studies. However, the potential for chance findings 
and bias from residual and unmeasured confounding is still possible. 
The conditional logistic regression models were adjusted for the selec-
tion bias introduced by the matching. However, this study is based on a 
small sample size, which limited the possibility to detect weak 
associations. The T2DM cases were chosen based on self-reported T2DM 
from questionnaires and were not confirmed by blood tests, as these 
blood samples were delivered several years before the present analyses. 
However, self-reported T2DM in the NOWAC study has been previously 
validated (Rylander et al., 2014). It should also be considered that the 
generalizability of this study may be limited to an older female Nor-
wegian population. 
This study adds to the evidence that neither pre- nor post-diagnostic 
measurements of PFAAs are associated with incident or prevalent 
T2DM, and that the temporal changes in PFAA concentrations are si-
milar within T2DM cases and controls. Together, this suggests that 
cross-sectional studies of prevalent T2DM and PFAAs do not create 
biased results, as T2DM status, or post-diagnostic weight change merely 
influence longitudinal changes in PFAAs concentrations after diagnosis. 
5. Conclusions 
We observed no association between pre- or post-diagnostic PFAA 
concentrations and T2DM. The observed longitudinal changes in PFAA 
concentrations from pre- to post-T2DM diagnosis in cases were similar 
to the changes in controls. 
Ethics approval and consent to participate 
The NOWAC study has been approved by the Norwegian Data 
Inspectorate and the Regional Committee for Medical Research Ethics 
in Northern Norway. The present study was approved by the Regional 
Committee for Medical Research Ethics (REK, case number: 2015/ 
1780). All participants provided written informed consent. 
Table 2 
Odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between a one-interquartile range increase in perfluoroalkyl acid concentrations, and 50 
ranks increase for the sum of PFAAs compounds and type 2 diabetes mellitus in case-control group 1 (matched by age, n = 44).        
T1 (pre-diagnosis) T2 (post-diagnosis) 
PFAA compounds(ng/mL) Age adjusted OR 
(95% CI) 
Multivariable adjusted OR 
(95% CI) 
Age adjusted OR 
(95% CI) 
Multivariable adjusted OR 
(95% CI)  
PFOA 0.73 (0.43, 1.28) 0.65 (0.34, 1.26) 0.74 (0.44, 1.25) 0.67 (0.36, 1.26) 
PFNA 0.83 (0.52, 1.32) 0.80 (0.47, 1.36) 0.91 (0.53, 1.55) 0.80 (0.43, 1.48) 
PFDA 0.88 (0.57, 1.38) 0.89 (0.55, 1.44) 0.85 (0.56, 1.30) 0.85 (0.53, 1.36) 
PFUnDA 0.82 (0.54, 1.23) 0.83 (0.54, 1.26) 0.88 (0.55, 1.39) 0.90 (0.54, 1.53) 
∑PFHxS 0.79 (0.56, 1.12) 0.72 (0.49, 1.05) 0.87 (0.63, 1.21) 0.80 (0.54, 1.20) 
∑PFHpS 0.88 (0.62, 1.24) 0.84 (0.57, 1.24) 0.87 (0.61, 1.25) 0.87 (0.56, 1.34) 
∑PFOS 0.88 (0.63, 1.22) 0.87 (0.60, 1.25) 0.84 (0.58, 1.20) 0.84 (0.55, 1.28) 
∑PFAAs 0.93 (0.79, 1.10) 0.91 (0.76, 1.10) 0.93 (0.79, 1.09) 0.89 (0.73, 1.08) 
Abbreviations: T1, time 1 (2001/2); T2, time 2 (2005/6); PFOA, perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFDA, perfluorodecanoic acid; PFUnDA, 
perfluoroundecanoic acid; ∑PFHxS, sum perfluorohexane sulfonate; ∑PFHpS, sum perfluoroheptane sulfonate; ∑PFOS, sum perfluorooctane sulfonate ∑PFAAs, sum 
perfluoroalkyl acids. aThe models were adjusted for age, breastfeeding, fish, meat, dairy, fruits and vegetables intake.  
Table 3 
Odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between a one-interquartile range increase in perfluoroalkyl acid concentrations, and 50 
ranks increase for the sum of PFAAs compounds and type 2 diabetes mellitus in case-control group 2 (n = 41).        
T1 (pre-diagnosis) T2 (post-diagnosis) 
PFAA compounds 
(ng/mL) 
Age + BMI adjusted OR 
(95% CI) 
Multivariable adjusted OR 
(95% CI)a 
Age + BMI adjusted OR 
(95% CI)a 
Multivariable adjusted OR 
(95% CI)a  
PFOA 0.61 (0.35, 1.06) 0.73 (0.41, 1.32) 0.55 (0.31, 0.99) 0.57 (0.31, 1.04) 
PFNA 0.94 (0.57, 1.57) 1.37 (0.69, 2.75) 0.97 (0.65, 1.43) 0.97 (0.64, 1.46) 
PFDA 1.00 (0.62, 1.64) 1.52 (0.76, 3.07) 1.03 (0.70, 1.52) 1.03 (0.68, 1.54) 
PFUnDA 0.93 (0.51, 1.70) 1.48 (0.64, 3.39) 1.21 (0.76, 1.92) 1.23 (0.75, 2.02) 
∑PFHxS 0.78 (0.53, 1.15) 0.70 (0.44, 1.09) 0.81 (0.58, 1.15) 0.76 (0.52, 1.11) 
∑PFHpS 0.92 (0.53, 1.59) 1.64 (0.71, 3.79) 0.87 (0.52, 1.44) 0.85 (0.50, 1.46) 
∑PFOS 0.81 (0.46, 1.42) 1.25 (0.57, 2.73) 0.79 (0.49, 1.28) 0.79 (0.48, 1.33) 
∑PFAAs 0.92 (0.79, 1.08) 1.00 (0.82, 1.24) 0.89 (0.75, 1.06) 0.88 (0.73, 1.06) 
Abbreviations: T1, time 1 (2001/2); T2, time 2 (2005/6); PFOA, perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFDA, perfluorodecanoic acid; PFUnDA, 
perfluoroundecanoic acid; ∑PFHxS, sum perfluorohexane sulfonate; ∑PFHpS, sum perfluoroheptane sulfonate; ∑PFOS, sum perfluorooctane sulfonate ∑PFAAs, sum 
perfluoroalkyl acids. aThe models were adjusted for age, BMI, breastfeeding, fish, meat, dairy, fruits and vegetables intake.  
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